Last reviewed · How we verify
Clindamycin/benzoyl peroxide gel
Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides additional antimicrobial and keratolytic effects.
Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides additional antimicrobial and keratolytic effects. Used for Acne vulgaris.
At a glance
| Generic name | Clindamycin/benzoyl peroxide gel |
|---|---|
| Also known as | Clindamcyin Phosphate, BPO, Duac® Gel |
| Sponsor | Actavis Inc. |
| Drug class | Antibiotic/keratolytic combination |
| Target | Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively eliminating Propionibacterium acnes. Benzoyl peroxide is an oxidizing agent that generates reactive oxygen species to kill bacteria and also helps normalize keratinization and reduce sebaceous gland activity. Together, they provide synergistic antibacterial and anti-inflammatory effects for acne treatment.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation/erythema
- Dryness
- Peeling
- Contact dermatitis
Key clinical trials
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne (PHASE4)
- A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. (PHASE1)
- Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations (NA)
- Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty (PHASE4)
- Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin/benzoyl peroxide gel CI brief — competitive landscape report
- Clindamycin/benzoyl peroxide gel updates RSS · CI watch RSS
- Actavis Inc. portfolio CI